Overview

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Fingolimod Hydrochloride